{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-26-000024","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2026-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.452477+00:00","generated_at":"2026-05-15T06:53:25.395131+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nurix Q1 net loss $87.2M ($0.79); advancing bexobrutideg registrational program","bullets":["Revenue $6.3M vs $18.5M YoY; net loss $87.2M ($0.79) vs $56.4M ($0.67).","Cash $540.7M vs $592.9M at Nov 30, 2025; net burn ~$52M in quarter.","Enrolling Phase 2 DAYBreak CLL-201 for bexobrutideg; Phase 3 confirmatory trial planned mid-2026.","Healthy volunteer SAD/MAD study of new tablet formulation to support IND in immunology/inflammation.","Sanofi advancing STAT6 degrader NX-3911; Gilead advancing IRAK4 degrader GS-6791 in Phase 1."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-26-000024","json":"https://secwatch.observer/filing/0001549595-26-000024.json","markdown":"https://secwatch.observer/filing/0001549595-26-000024.md","text":"https://secwatch.observer/filing/0001549595-26-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000024/0001549595-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000024/nrix-20260408.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:53:25.395131+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7da8c9134e083a6422bf1705c9fa619efdbd0e26","claim":"Nurix Therapeutics, Inc. reported the fiscal quarter ended February 28, 2026 results: revenue $6.3 million.","evidence_excerpt":"Revenue for the three months ended February 28, 2026, was $6.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000024/0001549595-26-000024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended February 28, 2026"},{"label":"Revenue","value":"$6.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}